Plaintiffs involved in a growing litigation of Lipitor lawsuit claims may soon find out whether their cases will be consolidated in a multidistrict proceeding.
According to court documents, the U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear oral arguments on the matter at its upcoming hearing on February 6, 2014 at 9:00 a.m. in New Orleans. This meeting was rescheduled from January 30th, when complications from Winter Storm Leon resulted in a postponement caused by flight cancellations and other transportation issues in the Louisiana city. At its upcoming hearing, the Panel will discuss the cholesterol stain’s alleged potential to cause new-onset Type 2 diabetes, a complication that has been noted in numerous Lipitor lawsuit filings.
The Panel’s upcoming decision on whether to centralize Lipitor diabetes lawsuits will have been prompted by plaintiffs’ recent request to do so, given the increasing number of claims filed in the U.S. According to recent records, at least 100 claims have now been filed against the drug’s manufacturer, Pfizer Inc., in federal courts throughout the country. Earlier this year, the JPML rejected a similar request for a multidistrict litigation on the grounds that there were not enough Lipitor lawsuits to warrant one. At the time of the April 2013 request, only about a dozen cases had been filed.
Among other things, Lipitor lawsuits similarly allege that the cholesterol-lowering statin may lead to new-onset Type 2 diabetes, as well as kidney and liver damage and skeletal muscle injuries. Plaintiffs go on to say that Pfizer failed to adequately warn about these risks when marketing the medication, even after the FDA issued a mandate in February 2012 requiring the company to include Lipitor’s risk for diabetes on its labeling. Plaintiffs argue that this alert is insufficient, and that the medication is designed defectively given its potential to cause serious side effects.
Where the number of lawsuits filed over Lipitor has grown, so has the amount of evidence surrounding its association with Type 2 diabetes. In January 2012, research published in JAMA: Internal Medicine found an increased risk for the disease in post-menopausal women who took the statin.
The attorneys at Bernstein Liebhard LLP are actively investigating Lipitor lawsuit claims on behalf of individuals who may have developed diabetes after taking the statin. Call our Firm today to learn more at .